NIPD Genetics announces the addition of six new NeoThetis liquid biopsy tests for therapy selection, which include Breast & Gynecological, Gastric, Melanoma, Pancreatic, Prostate and Pan-Cancer. With a simple blood draw, patients diagnosed with cancer can have fast, safe, and accurate results that can guide therapy selection for primary and metastatic disease, and treatment re-evaluation for therapy resistance.
Fostering over a decade of research excellence in the field of genetic testing and cell-free DNA, NeoThetis was specifically designed to deliver superior performance and clinically actionable results. NeoThetis liquid biopsy was first launched in 2021 with NeoThetis Colorectal and NeoThetis NSCLC. As a non-invasive test, NeoThetis can overcome some of the challenges concerning tumour inaccessibility and the inability to assess metastatic lesions. Apart from testing for genetic alterations, all 8 NeoThetis tests include testing of Microsatellite Instability, a predictive biomarker for immunotherapy treatment, with results reported within 6-9 working days.
Professor Philippos Patsalis, Founder and CEO of NIPD Genetics, stated that “Our primary goal has always been to enhance the patient’s clinical management and care opportunities by delivering highly accurate genetic results. We believe that with the launch of the new NeoThetis tests, which are based on our proprietary and sophisticated technology platform, we respond to the patients’ and market needs, providing non-invasive alternative options for genetic testing.”
NIPD Genetics, a Medicover company is recognized as an international beacon of excellence in the field of biotechnology and genetic testing. It offers a spectrum of oncology services which include hereditary cancer screening, tumour profiling of solid tumours and liquid biopsy for therapy selection and re-evaluation. Through the NeoThetis tests, NIPD Genetics highlights its dedication to helping numerous patients in their journey to cancer treatment and accurate prognosis, and in empowering healthcare providers to take informed decisions which enhance clinical management and treatment of patients.
